PF-06446846

CAT: 0804-HY-120088Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-120088Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region[1].
CAS Number
[1632250-49-7]
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
PCSK9
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pf-06446846.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(C=C1)N2N=NC3=CC=CN=C32)N([C@H]4CNCCC4)C5=NC=CC=C5Cl
Molecular Formula
C22H20ClN7O
Molecular Weight
433.89
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Nathanael G Lintner, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2018 Apr 17;16 (4) :e1002628.|[2]Allyn T. Londregan, et al. Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. J Med Chem. 2018 Jul 12;61 (13) :5704-5718.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Cancer Commun (Lond) . 2025 Aug;45 (8) :1010-1037.|Arch Oral Biol. 2025 May 21:176:106302.|BMC Cancer. 2024 Apr 10;24 (1) :445.|Int J Biol Sci. 2024 Jul 15;20 (10) :3942-3955.|Protein Cell. 2021 Apr;12 (4) :240-260.|SSRN. 2025 Jun 18.

Popular Products